Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Siblings trying to make US water polo teams for Paris Olympics
Letter from Lhasa: A return after 14 years
Opinion: How the G7 glorifies the hypocrisy and selfishness of the United States
Perenara equals Super Rugby try
Inquiry slams UK authorities for failures that killed thousands in infected blood scandal
To build even closer relations between China, Central Asian countries
Middle East welcomes China's role as peace builder, rejects US determinism
2023 'My Story of Chinese Hanzi' international competition wraps up in N China's Jincheng
Lynn Williams breaks NWSL goal
Farewell to China's homecoming motorbike fleets
Rangers are undefeated at .500 to keep World Series champs from a losing record with Bochy
Xi presents order to promote military officers to rank of general